107. Juvenile idiopathic arthritis Clinical trials / Disease details

Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04775225 (ClinicalTrials.gov)	January 6, 2021	17/2/2021	Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis	Hip Denervation in Juvenile Idiopathic Arthritis	Juvenile Idiopathic Arthritis;Hip Arthritis	Drug: Lidocaine;Drug: Placebo;Drug: Steroid	Sohag University	NULL	Completed	2 Years	18 Years	All	120	Phase 3	Egypt
2	NCT04687930 (ClinicalTrials.gov)	December 1, 2020	19/12/2020	Genicular Nerve Block in Juvenile Idiopathic Arthritis	Genicular Nerve Block in Juvenile Idiopathic Arthritis	Juvenile Idiopathic Arthritis;Persistent Knee Arthritis;no Intra-articular Injection in the Last 3 Months;no Other Cause for Chronic Kneearthritis	Drug: genicular nerve block;Drug: intra-articular steroid injection	Sohag University	NULL	Completed	N/A	16 Years	All	104	Phase 4	Egypt
3	EUCTR2018-004284-30-DE (EUCTR)	13/02/2020	29/07/2019	Repsonse to Treatment with Canakinumab without steroids early after diagnosis of systemic onset juvenile idiopathic arthritis / juvenile Still’s disease	Effectiveness of Canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis / juvenile Still’s disease - CANAKINUMAB FIRST	systemic juvenile idiopathic arthritis MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Ilaris Product Name: Ilaris	Asklepios Klink Sankt Augustin	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Germany
4	NCT00868751 (ClinicalTrials.gov)	March 2009	24/3/2009	Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis	Single Patient Use of Tocilizumab for Treatment of Steroid Dependent, Active Systemic Onset Juvenile Idiopathic Arthritis	Arthritis, Juvenile Rheumatoid;Still's Disease, Juvenile Onset	Biological: tocilizumab	Tufts Medical Center	Hoffmann-La Roche	Terminated	2 Years	16 Years	All	1	N/A	United States
5	JPRN-UMIN000001457	2008/10/01	28/10/2008	The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial	The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial - Efficacy assessment of tocilizumab to steroid-resistant patients with adult Still's disease	Adult Still's disease and systemic juvenile idiopathic arthritis	Tocilizumab is to be infused every 2 to 4 weeks at 8 mg/kg of body weight	Division of Rheumatology & Clinical Immunology, Jichi Medical University	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	10	Not selected	Japan
6	JPRN-UMIN000001250	2008/07/01	16/07/2008	Study on the glucocorticoid-sparing effects of tocilizumab among glucocorticoid-dependent patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial	Study on the glucocorticoid-sparing effects of tocilizumab among glucocorticoid-dependent patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial - Effects of tocilizumab-addition to steroid-dependent patients with adult Still's disease	Adult Still's disease or systemic juvenile idiopathic arthritis	Tocilizumab (8 mg/kg of body weight) is to be infused every 2 to 4 weeks.	Division of Rheumatology & Clinical Immunology, Jichi Medical University	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	10	Not selected	Japan
7	NCT00642460 (ClinicalTrials.gov)	May 2008	19/3/2008	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)	A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab	Juvenile Idiopathic Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Placebo;Drug: Non-steroidal anti-inflammatory drugs (NSAIDs);Drug: methotrexate;Drug: corticosteroids	Hoffmann-La Roche	NULL	Completed	2 Years	17 Years	All	112	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;France
8	EUCTR2005-003129-23-GB (EUCTR)	18/04/2006	24/02/2006	To prevent and treat osteoporosis in children with rhuematic diseases taking steroids	Prevention and Treatment of Steroid-Induced Osteopenia in children and adolescents with rheumatic diseases - POPS	Children and adolescents with Juvenile Idiopathic arthritis (JIA), Juvenile dermatomyositis (JDMS) Juvenile systemic lupus erythematosis (JSLE) Vasculitis;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Risedronate Sodium Product Code: 35mg Other descriptive name: RISEDRONATE SODIUM Product Name: Risedronate Sodium Product Code: 5mg Other descriptive name: RISEDRONATE SODIUM Trade Name: One-Alpha drops Product Name: One Alpha Drops Product Code: alfacalcidol 2 micrograms/ml INN or Proposed INN: ALFACALCIDOL Other descriptive name: drops	Belfast Health and Social Care Trust, Musgrave Park Hospital	NULL	Not Recruiting			Female: yes Male: yes	216	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom